Application of daphnetin in preparation of medicine for treating renal clear cell carcinoma
By preparing revanol as an active ingredient as a renal clear cell carcinoma drug, the problem of failure to effectively use revanol alone in the prior art to inhibit renal clear cell carcinoma is solved, and the proliferation, migration and invasion of renal clear cell carcinoma cells is achieved. Inhibition and significant inhibition of tumor growth provide new therapeutic strategies.
Patent Information
- Application Number
- CN202411436642.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art has failed to effectively use revanol to inhibit the treatment of renal clear cell carcinoma alone. Although the combination of revanol and other anti-tumor drugs has shown inhibitory effects on other types of cancer, research on renal clear cell carcinoma insufficient.
Revanin is used as the only active ingredient or one of the active ingredient to prepare drugs for gastrointestinal administration, including granules, tablets, capsules or oral liquid preparations, for the inhibition of renal clear cell carcinoma 786-O and 769-P cells proliferate, migrate, invade, and inhibit tumor growth by promoting apoptosis and blocking the cell cycle.
Revanin effectively inhibits the proliferation, migration and invasion of renal clear cell carcinoma cells, promotes apoptosis, blocks the cell cycle, significantly inhibits the growth of renal cancer transplant tumors and causes pathological tissue changes, providing a new therapeutic strategy for renal clear cell carcinoma.
Smart Images

Figure CN119015275A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and in particular relates to the application of daphnetin in preparing a medicine for treating renal clear cell carcinoma. Background Art
[0002] Renal cell carcinomas (RCCs) are among the top ten most common cancers and the most common family of kidney tumors. Among all its subtypes, clear cell RCC (ccRCC) is the most common type of sporadic renal cancer, accounting for approximately 75% of all cases, and is often associated with malignant disease progression and poor treatment outcomes.
[0003] Daphnetoside, whose chemical name is 7,8-dihydroxycoumarin, is mainly found in plants of the Thymelaeaceae family. It is an inhibitor of multiple kinases and has multiple pharmacological effects, including analgesia, anti-malarial, anti-arthritis and antipyretic. It is widely used in the auxiliary treatment of thromboangiitis obliterans and other occlusive vascular diseases and coronary heart disease.
[0004] It has been reported that daphneline has an inhibitory effect on a variety of tumor cells, including inhibiting breast cancer through the MAPK1 / 2-JNK1 / 2-Akt pathway, inhibiting liver cancer by acting on the Bcl-1 / Bax target, inhibiting lung adenocarcinoma through the Akt / NF-κB pathway, and inhibiting ovarian cancer through AMPK / Akt / mTOR. The patent "A combined anti-tumor drug" with the authorization number CN109453164B discloses that daphneline and other anti-tumor drugs have significant anti-tumor effects after being used in combination. The patent uses the combined drug on human cervical cancer cells HeLa, human breast cancer cell lines MCF-7, and MDA-MB-231, and combines in vitro transplant tumor experiments to verify that the combination of daphneline and anti-tumor drugs can inhibit the proliferation of the above cell lines. Although the prior art has verified that the combined use of daphneline and anti-tumor drugs has an inhibitory effect on cervical cancer and breast cancer, it does not disclose the inhibitory effect of daphneline alone on renal clear cell carcinoma. Summary of the invention
[0005] The purpose of the present invention is to provide a new use of daphnetin for treating renal clear cell carcinoma, specifically the use of daphnetin in the preparation of a drug for treating renal clear cell carcinoma.
[0006] The technical solution of the present invention:
[0007] Application of daphnetin in preparing medicine for treating renal clear cell carcinoma.
[0008] Furthermore, the drug for treating renal clear cell carcinoma contains daphnetin as the only active ingredient or one of the active ingredients.
[0009] Furthermore, the content of daphnetin in the drug for treating renal clear cell carcinoma is 0.1wt% to 99wt%.
[0010] Furthermore, the drug for treating renal clear cell carcinoma also includes a pharmaceutically acceptable excipient.
[0011] Furthermore, the drug for treating renal clear cell carcinoma is in a dosage form for administration via the gastrointestinal tract.
[0012] Furthermore, the dosage form of the drug for treating renal clear cell carcinoma is granules, tablets, capsules, pills or oral liquid preparations.
[0013] Furthermore, the drug for treating renal clear cell carcinoma can inhibit the proliferation and apoptosis of renal clear cell carcinoma 786-O cells and 769-P cells.
[0014] Furthermore, the drug for treating renal clear cell carcinoma can inhibit the cell migration and invasion of renal clear cell carcinoma 786-O cells and 769-P cells.
[0015] Furthermore, the drug for treating renal clear cell carcinoma can block renal clear cell carcinoma 786-O cells and 769-P cells in the G0 / G1 phase.
[0016] Furthermore, the drug for treating renal clear cell carcinoma can effectively inhibit the growth of renal clear cell carcinoma transplanted tumors.
[0017] Furthermore, the drug for treating renal clear cell carcinoma can induce pathological tissue changes in renal clear cell carcinoma transplanted tumors.
[0018] Beneficial effects of the present invention:
[0019] The present invention makes full use of the advantages of traditional Chinese medicine with multiple components, multiple targets and few adverse reactions, uses daphnetin to act on renal clear cell carcinoma cell lines 786-O and 769-P, and combines experiments to verify that daphnetin has the effect of inhibiting 786-O and 769-P cell proliferation, migration and invasion, and promoting apoptosis of both cells. Animal experiments have confirmed that daphnetin can effectively inhibit the growth of renal clear cell carcinoma transplants, cause pathological tissue changes in renal clear cell carcinoma transplants, and significantly inhibit the development of renal cancer. The present invention provides a new use of daphnetin for treating renal clear cell carcinoma, specifically the use of daphnetin in the preparation of a drug for treating renal clear cell carcinoma, which provides an experimental basis and a new strategy for the clinical treatment of renal clear cell carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 From left to right are the comparison charts of OD values of 769-P cells and 786-O cells in CCK8 experiment;
[0021] Figure 2From left to right are the comparison diagrams of the inhibition rate of daphnetoin on the proliferation of 769-P cells and 786-O cells in the CCK8 experiment;
[0022] Figure 3 These are the staining photos of 769-P cells and 786-O cells in the CON group and RXS group in the crystal violet staining experiment;
[0023] Figure 4 From left to right are the comparison of staining areas of 769-P cells and 786-O cells in the CON group and RXS group in the crystal violet staining experiment;
[0024] Figure 5 The scatter plots of 769-P cells and 786-O cells in the CON group and RXS group detected by flow cytometry;
[0025] Figure 6 From left to right are the comparison of apoptotic cell percentages of 769-P cells and 786-O cells in the CON group and RXS group detected by flow cytometry;
[0026] Figure 7 Cell migration images of 769-P cells in the CON and RXS groups in the scratch assay;
[0027] Figure 8 Cell migration images of 786-O cells in the CON and RXS groups in the scratch assay;
[0028] Fig. 9 This is a comparison of the cell migration rates of 769-P cells in the CON group and the RXS group in the scratch assay;
[0029] Fig.10 This is a comparison of the cell migration rates of 786-O cells in the CON group and the RXS group in the scratch assay;
[0030] Fig.11 Crystal violet staining images of 769-P cells in the CON and RXS groups in the Transwell experiment;
[0031] Fig.12 Crystal violet staining images of 786-O cells in the CON and RXS groups in the Transwell experiment;
[0032] Fig.13 From left to right are the comparison of the number of cells that achieved invasion in 769-P cells and 786-O cells in the CON group and RXS group in the Transwell experiment;
[0033] Fig.14 The flow cytometric cell cycle analysis of 769-P cells and 786-O cells in the CON and RXS groups obtained by PI staining;
[0034] Fig.15 This is a comparison of DNA content in 769-P cells of CON group and RXS group at different cell cycles by PI staining;
[0035] Fig.16 Comparison of DNA content in 786-O cells of CON group and RXS group at different cell cycles by PI staining;
[0036] Fig.17 This is a comparison chart of the volume of transplanted tumors in the CON group and RXS group in the animal model experiment;
[0037] Fig.18 These are HE staining photos of transplanted tumor tissues in the CON group and RXS group in the animal model experiment. DETAILED DESCRIPTION
[0038] The technical solution of the present invention is further described below in conjunction with the embodiments, but it is not limited thereto. Any modification or equivalent replacement of the technical solution of the present invention without departing from the spirit and scope of the technical solution of the present invention shall be included in the protection scope of the present invention. The process equipment or devices not specifically noted in the following embodiments are all conventional equipment or devices in the art. If not specifically specified, the raw materials used in the embodiments of the present invention can be obtained commercially; if not specifically specified, the technical means used in the embodiments of the present invention are all conventional means well known to those skilled in the art.
[0039] In the examples of the present invention, Daphnetin was purchased from Shanghai Yuanye Biotechnology Co., Ltd., CCK8 reagent, crystal violet dye, 1640 culture medium were purchased from White Shark Biotechnology Co., Ltd., and apoptosis kit and cell cycle kit were purchased from Aibixin Biotechnology Co., Ltd.
[0040] In each example, the renal clear cell carcinoma 786-O and 769-P cells were cultured in 1640 medium (10% fetal bovine serum, 1% double antibody), 5% CO2, and 37°C cell culture incubator.
[0041] Example 1
[0042] In this example, the CCK8 method was used to verify the inhibitory effect of daphnetin on the proliferation of renal clear cell carcinoma 786-O and 769-P cells.
[0043] In this example, the CCK8 experiment was divided into a blank CON group and a daphneline RXS group. The renal clear cell carcinoma 786-O cells and renal clear cell carcinoma 769-P cells were cultured at 3×10 3Each well was inoculated into a 96-well plate and cultured at 37°C overnight. The next day, the daphnetin group was given medication at doses of 20, 40, and 60 μM. CCK8 reagent was added to each well 24 h, 48 h, and 72 h after medication, respectively. After incubation for 1.5 h, the absorbance at 450 nm was detected using an enzyme reader.
[0044] Figure 1 This is a comparison of the OD values of daphnetoin on renal clear cell carcinoma 786-O and 769-P cells in the CCK8 experiment; Figure 2 This is a comparison chart of the inhibition rate of daphneline on the proliferation of renal clear cell carcinoma 786-O and 769-P cells in the CCK8 experiment; the picture shows that over time, the OD value of the control group continued to increase, showing a typical cell proliferation exponential growth trend; while the OD value of the daphneline group increased slowly, indicating that cell proliferation was continuously inhibited, and the 48h inhibition rate was higher than the 24h inhibition rate. This proves that daphneline has an inhibitory effect on the proliferation of renal clear cell carcinoma 786-O and 769-P cells.
[0045] Example 2
[0046] In this example, crystal violet dye was used to detect the effect of daphnetin on the proliferation of renal clear cell carcinoma 786-O and 769-P cells.
[0047] In this example, the cells were divided into a blank CON group and a daphneline RXS group. The renal clear cell carcinoma 786-O cells and renal clear cell carcinoma 769-P cells were expressed at 1.5×10 3 Cells were inoculated into 6-well plates. The daphnetin group was administered with suspension at a dosage of 60 μM. The medium was changed every two days. After the cells in the blank group were fully grown, they were fixed with 4% paraformaldehyde for 15 min, stained with crystal violet solution for 30 min, and photographed under a microscope.
[0048] Figure 3 These are the staining photos of 786-O and 769-P cells in the CON and RXS groups in the crystal violet staining experiment; Figure 4 This is a comparison of the staining areas of 786-O and 769-P cells in the CON group and the RXS group in the crystal violet staining experiment; the picture shows that under the same conditions of crystal violet staining, the staining color of the cells in the daphneline group was significantly lighter than that in the control group, indicating that the cell proliferation in the daphneline group was inhibited, resulting in reduced replication and synthesis of DNA in the cells. This proves that daphneline inhibits the proliferation of renal clear cell carcinoma 786-O and 769-P cells.
[0049] Example 3
[0050] This example uses flow cytometry to verify that daphnetin can promote apoptosis of renal clear cell carcinoma 786-O and 769-P cells.
[0051] In this example, the cells were divided into a blank CON group and a daphneline RXS group. The renal clear cell carcinoma 786-O cells and renal clear cell carcinoma 769-P cells were expressed at 10×10 4 The cells were inoculated into 6-well plates and cultured at 37°C overnight. The next day, the daphnetolide group was given the drug at a dosage of 60 μM. 48 hours after the drug administration, the cells were digested and centrifuged, and stained with Annexin V-FITC / PI double staining method. Flow cytometry was used to detect cell apoptosis in the two groups.
[0052] Figure 5 The scatter plots of 786-O and 769-P cells in the CON and RXS groups detected by flow cytometry; Figure 6 This is a comparison of the percentage of apoptotic cells of 786-O and 769-P in the CON group and the RXS group; the picture shows that the number of scattered points in the upper right quadrant and the lower right quadrant of the 786-O and 769-P daphnetin-treated group is more than that of the control group, which indicates that the number of early apoptotic cells and late apoptotic or necrotic cells produced in the daphnetin-treated group is increased, and therefore, the percentage of apoptotic cells is also greater. This proves that daphnetin can promote apoptosis of renal clear cell carcinoma 786-O and 769-P cells.
[0053] Example 4
[0054] This example uses a scratch experiment to verify that daphnetin can inhibit the migration of renal clear cell carcinoma 786-O and 769-P cells.
[0055] In this example, the cells were divided into a blank CON group and a daphneline RXS group. The renal clear cell carcinoma 786-O cells and the renal clear cell carcinoma 769-P cells were inoculated into a 6-well plate at 5×104 cells / well. The cells covered the bottom of the well and then scratched it. At the same time, the daphneline group was given the drug at a dosage of 60 μM. The migration of the cells was observed under a microscope 24 h, 48 h, and 72 h after the drug administration.
[0056] Figure 7 and Figure 8 These are the cell migration images of 769-P and 786-O cells in the CON and RXS groups in the scratch assay, respectively; Fig. 9 and Fig.10 These are comparisons of cell migration rates of 769-P and 786-O cells in the CON group and RXS group in the scratch test; the pictures show that at the same observation time point, the migration rate of cells in the CON group was higher than that in the daphneline group. The comparison of cell migration rates also shows that the migration ability of cells in the CON group is stronger than that in the daphneline group. This proves that daphneline can inhibit the migration of renal clear cell carcinoma 786-O and 769-P cells.
[0057] Example 5
[0058] This example uses a Transwell assay to verify that daphnetin can inhibit the invasion of renal clear cell carcinoma 786-O and 769-P cells.
[0059] In this example, the cells were divided into a blank CON group and a daphneline RXS group. The renal clear cell carcinoma 786-O cells and renal clear cell carcinoma 769-P cells were expressed at 5×10 4 The cells were inoculated into the Transwell chamber containing matrix gel. The daphnetin group was administered by suspension at a dosage of 60 μM. After 48 h of action, they were fixed with 4% paraformaldehyde and stained with crystal violet dye. After washing with clean water, the cells were photographed under a microscope to observe the invasion of the two groups of cells.
[0060] Fig.11 and Fig.12 These are the crystal violet staining images of 769-P and 786-O cells in the CON and RXS groups in the Transwell experiment, respectively; Fig.13 This is a comparison of the number of cells that achieved invasion in the CON group and the RXS group 769-P and 786-O in the Transwell experiment; the picture shows that the density of crystal violet-stained cells in the CON group is higher than that in the daphneline group, and the number of cells that achieved invasion is greater, which indicates that the cells in the CON group have stronger invasion ability. This shows that daphneline can inhibit the invasion of renal clear cell carcinoma 786-O and 769-P cells.
[0061] Example 6
[0062] This example uses flow cytometry to verify that daphnetoin can block renal clear cell carcinoma 786-O and 769-P cells in the G0 / G1 phase.
[0063] In this example, the cells were divided into a blank CON group and a daphneline RXS group. The renal clear cell carcinoma 786-O cells and renal clear cell carcinoma 769-P cells were expressed at 10×10 4 Each well was inoculated into a 6-well plate and cultured at 37°C overnight. The next day, the daphnetolide group was given the drug at a dosage of 60 μM. 48 hours after the drug administration, the cells were digested and centrifuged and fixed with 75% alcohol at 4°C overnight. The next day, they were stained with PI staining method, and the cell cycle of the two groups was detected by flow cytometry.
[0064] Fig.14 The flow cytometric cell cycle analysis of 769-P and 786-O cells in the CON and RXS groups obtained by PI staining; Fig.15 and Fig.16The figures are the comparison of DNA content of CON group and RXS group 769-P and 786-O cells in different cell cycles in PI staining method; the figure shows that in the flow cytometry cell cycle analysis diagram, a sub-G1 peak was observed on the left side of the G0 / G1 peak in RXS group 769-P and 786-O, which usually represents apoptotic cells. During apoptosis, the release of intracellular nucleases will degrade DNA into small fragments. These fragments cannot form a complete 2N peak when PI staining, but form a sub-G1 peak. Therefore, the presence of sub-G1 peak can reflect the apoptosis of cells. At the same time, RXS group 769-P and 786-O cells showed more G0 / G1 phase cells, indicating that the proliferation rate of cells in this group was slower. This proves that daphne can block renal clear cell carcinoma 786-O and 769-P cells in the G0 / G1 phase and stop tumor cell proliferation.
[0065] Example 7
[0066] This example verifies that daphnetin can inhibit the growth of renal clear cell carcinoma by constructing a renal clear cell carcinoma transplanted tumor mouse model. In the example, the transplanted tumor was constructed using 786-O cells and Nu / Nu nude mice.
[0067] In this example, nude mice were subcutaneously inoculated with 1×107 786-O renal cancer cells in the armpits, and were randomly divided into the CON group and the RXS group after tumors appeared. The RXS group was intraperitoneally injected with 30 mg / kg daphne solution every day, and the CON group was given an equal amount of normal saline in the same way for 12 days. During this period, the volume of the transplanted tumor was measured and recorded every day. The growth of the transplanted tumors in the two groups was calculated and compared.
[0068] Fig.17 The figure is a comparison chart of the calculated tumor volumes of the CON group and the RXS group. The figure shows that the tumor volume of the RXS group nude mice during the drug administration period was significantly smaller than that of the CON group. This shows that daphnetolide can significantly inhibit the growth of renal cancer.
[0069] In this example, HE staining observation of transplanted tumor tissue sections was performed to verify that daphnetin could induce pathological tissue changes in renal clear cell carcinoma transplanted tumors.
[0070] Fig.18 The following are HE staining photos of transplanted tumors in the CON and RXS groups. The pictures show that the CON group has the largest number of tumor cells, which are tightly arranged, have complete structures, have complete and clear cell nuclei, and have less interstitial tissue. The RXS group has fewer tumor cells than the CON group, with looser arrangements, cell nuclei beginning to dissolve, necrotic cells appearing, cytoplasmic staining signals weakening, and interstitial tissue enlarging. This shows that daphneline can significantly inhibit the development of renal cancer.
Claims
1. Application of daphnetin in the preparation of drugs for treating renal clear cell carcinoma.
2. The use of daphnetin according to claim 1 in the preparation of a drug for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma uses daphnetin as the only active ingredient or one of the active ingredients.
3. The use of daphnetin according to claim 2 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The content of daphnetin in the drug for treating renal clear cell carcinoma is 0.1wt% to 99wt%.
4. The use of daphnetin according to claim 3 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma also includes pharmaceutically acceptable excipients.
5. Use of daphnetin according to claim 4 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma is in the form of a gastrointestinal tract administration dosage form.
6. Use of daphnetin according to claim 5 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma can inhibit the proliferation and apoptosis of renal clear cell carcinoma 786-O cells and 769-P cells.
7. Use of daphnetin according to claim 6 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma can inhibit the cell migration and invasion of renal clear cell carcinoma 786-O cells and 769-P cells.
8. Use of daphnetin according to claim 7 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma can block renal clear cell carcinoma 786-O cells and 769-P cells in the G0 / G1 phase.
9. Use of daphnetin according to claim 8 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma can effectively inhibit the growth of renal clear cell carcinoma transplanted tumors.
10. Use of daphnetin according to claim 9 in the preparation of a medicament for treating renal clear cell carcinoma, It is characterized in that The drug for treating renal clear cell carcinoma can induce pathological tissue changes in renal clear cell carcinoma transplanted tumors.
Citation Information
Patent Citations
A combination anti-tumor drug
CN109453164B
Cited By
Pharmaceutical composition for preventing and treating lung cancer
CN119656217A
Application of daphnetin in thyroid nodule treatment medicine
CN121714562A
